High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...

Cumberland Pharmaceuticals saw its shares pop almost 34 percent on heavy volume Tuesday following positive results from a ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.53 and traded as ...

NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...

Cumberland Pharmaceuticals stock opened at $2.43 on Tuesday. The business’s fifty day moving average is $1.93 and its two-hundred day moving average is $1.54. The company has a debt-to-equity ...

Shares of Cumberland Pharmaceuticals continued their eye-opening ascent Wednesday on heavy volume.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...